IVD market 2026: which test systems register in 2 months, and which ones only after a full cycle?

The year 2026 was a turning point for manufacturers of in vitro diagnostics in Russia. On January 1, new EAEU rules for IVD products came into force, and Roszdravnadzor launched a pilot for accelerated registration for test strips and rapid tests included in the list of critical ones. At the same time, some of the foreign brands have finally left, freeing up niches. We are looking at which categories are currently registering the fastest, where the real demand is, and which "traps" of 2026 need to be taken into account.
1. Top 5 IVD categories that are easiest to register in 2026
• Rapid tests for respiratory infections (influenza A+B, COVID-19, RSV, adenovirus). Relevant: since 2026, a permanent simplified procedure has been in effect under Resolution No. 1862 (extended until 2028) — the registration period is 30-50 business days. Demand is consistently high due to seasonal outbreaks and government procurement for schools and hospitals.
• Glucose self-monitoring test strips (including those compatible with Continuous Glucose Monitoring). Relevant: since February 2026, the Ministry of Industry and Trade has expanded the list of essential goods, adding not only strips, but also lancets and control solutions. Registration period is up to 4 months, the fee is reduced by30%.
• ELISA kits for HIV, hepatitis B and C. Relevant: simplified mutual recognition of registrations within the EAEU has been in effect since 2025. If your product already has a certificate from Kazakhstan or Belarus, the registration period in the Russian Federation is 2-3 months without repeated clinical trials.
• Cancer markers (PSA, CA-125, CA19-9, HE4, CYFRA21-1). Relevant: private laboratories (Hemotest, Invitro, Helix) are actively replacing imported reagents with domestic analogues in 2026. The key requirement is a clinical sensitivity of at least 95%. Registration is standard, but if data from OECD countries are available, there are no Russian clinical trials.
• Hormones of the thyroid gland and the reproductive system (TSH, T3, T4, FSH, LH, prolactin, progesterone). Relevant: since March 2026, a "fast track" has been introduced for this category — if the manufacturer provides stability documents in accordance with GOST ISO 23640-2022 and the ISO 13485 certificate, the examination lasts 60 working days.
2. The main life hack of 2026: How to save 4-6 months
The agreement on the single market of IVD products of the EAEU entered into force on January 1, 2026. If your product has already been registered in any country of the Union (Kazakhstan, Belarus, Kyrgyzstan, Armenia), an application for quality confirmation is not submitted for registration, but for a period of 2-3 months. An important condition: documentation in Russian and production according to a single standard (ISO 13485). This reduces total costs by 40-60%.
3. What will surprise even experienced manufacturers in 2026
• It is no longer necessary to conduct separate clinical trials in the Russian population for most IVD products (except implantable and in vivo). Resolution No. 1545 of 2024 remains in force, and in 2026 Roszdravnadzor approved a list of 70 OECD countries, data from which are accepted without additional validation.
• From April 1, 2026, it is mandatory to mark with a QR code on each consumer package of test strips and rapid tests. The code should lead to a page in the unified register of Roszdravnadzor. It is forbidden to place goods without such a code in pharmacies and medical institutions.
• New GOST for stability — for IVD products with a shelf life of more than 18 months, it is now mandatory to provide data on accelerated aging (accelerated stability testing) according to GOST ISO 23640-2025 (updated version).
4. The pitfalls of 2026
• Reagents with sodium azide and thiomersal in concentrations above 0.01% are prohibited without special toxicological justification. If your tests contain these preservatives, prepare additional documents (it takes up to 3 months).
• Increased requirements for stability during transportation
5. The real case: how a startup from Kazan brought test strips to the market in 2.5 months
In February 2026, Bio-Express registered glucose test strips using the EAEU's new mutual recognition mechanism. The product already had a Belarusian certificate (received in December 2025). Instead of a complete set of documents, an application for quality assurance was submitted — the examination took 68 working days. Total savings:4 months of time and 1.2 million rubles for clinical trials. According to the CEO of the company, the key success factor was the pre-prepared documentation in Russian and the availability of ISO 13485 (quality management system certificate).
6. Forecast for 2026-2027: what will be in the trend
• Two-in-one hybrid tests that simultaneously identify the pathogen and the marker of inflammation (for example, influenza + procalcitonin). Roszdravnadzor has announced a separate simplified track for such products from the second quarter of 2026.
• Test systems for home use — in the wake of the self-care trend. There is a special demand for fertility kits, vitamin D and stress hormones (cortisol). Registration for "home" tests now requires additional usability engineering report according to GOST IEC 62366-1:2025.
• ELISA reagents for new biomarkers — microRNAs (miRNAs) for early diagnosis of lung and colorectal cancer. So far, there have been isolated applications, but the regulatory outline has already been formed.
7. A checklist for a manufacturer who wants to register an IVD in 2026 (briefly):
• Determine the HS code and the type of medical device (if you need a consultation, we will provide it for free).
• Prepare the technological documentation in Russian.
• Make sure that you have an ISO 13485 certificate (valid).
• Collect data on analytical and clinical validation (if there is data from the USA, EU, Japan — great, Russian trials are not needed).
• Design the packaging with a QR code (required from April 2026).
• Check the stability dates according to GOST ISO 23640-2025 (accelerated testing is required if the shelf life is >18 months).
• Eliminate prohibited preservatives (sodium azide >0.01% requires justification; thiomersal is completely banned from 2026).
The IVD market in 2026 is a window of opportunity that is closing for those who procrastinate. Simplified procedures, mutual recognition of the EAEU and the abolition of mandatory clinical trials for most tests — there has not been such a chance in the last 5 years. But the validity period of some exemptions is limited: for example, the simplified procedure under Resolution No. 1862 is valid only until 2028, and the unified register of the EAEU will begin operating in September 2026, after which reissue will become mandatory and more expensive.
Don't wait in lines. Leave a request right now. We will analyze your product for free and suggest the best way to register. We work with manufacturers from Russia, Belarus, Kazakhstan and other countries.